Dr. Albert Bourla
Thank you, Chuck, and good morning, everyone.
2020 was a year like none other in Pfizer’s history.
With the separation of Upjohn complete, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused Company.
Through our collaboration with BioNTech, we delivered the world’s first breakthrough COVID-19 vaccine in less than a year.
And by harnessing the power of variety of digital capabilities, we made sure that despite the lockdowns and travel restrictions, we continue to serve patients around the world who rely on our medicines and vaccines.
for and a amount vaccine, fourth we excluding safe X% the revenue COVID-XX environment devoted resources we BioNTech the challenging our Pfizer million operational develop from in in consumer recorded quarter. to and growth excluding revenue this impact the product that healthcare of incredible the we generated core from Despite biopharmaceutical year and portfolio, $XXX the vaccine effective of COVID-XX sales
X% this due that mind growth in includes and impact in Keep resulting X% negative operational pandemic. to macroeconomic a slowdown the from healthcare activity the
This the operational the was primarily drivers growth of Xtandi, U.S., Biosimilars, Oncology performances by continued and growth contributed Vyndaqel/Vyndamax, significantly. Eliquis, from outside driven Prevenar Inlyta, all XX basically Ibrance, Xeljanz strong so
adjusted up operationally EPS to year diluted $X.XX XX%, was XXXX. from Full
would associated expenses as our revenues to with been point operations the adjusted and I out recategorized that have from excluded discontinued business and like results. Upjohn
which as the past had focused I for a envisioned So, as to have biopharmaceutical company, us global we positions strong several overall, one operate begin which we year, well years.
$X.X start in operationally. of with a of our up of growth XXXX, Vyndaqel me and generated revenues some drivers. XXX% Vyndamax Let key discussion billion
we appropriate from Our of XX% before rate at with X education the compared diagnosis, the to fourth continued disease launched, to to efforts X% support approximately end diagnosis XX. increasing more than quarter as
cost diagnosed, assistant have received more of who the than As at including than received than patient have programs. been patients drug more patients drug, have the our more patients XX,XXX prescription, no X,XXX December XX,XXX received and XXst, through patients
gradual in patient starts. in and We continue new since new diagnosis QX to rebound the recovery a see
channel strong number lockdowns for varying we to in an unfavorable resurgence well billion of price operationally $X.X performance Eliquis the of the that another lower of XXXX, year. as the current delivered U.S., partially offset of a gap, by original and to was the the however, are due revenues with as XX% impact this Medicare In coverage growth increased net recovery. up could expansion With lives seeing gap, COVID-XX, strong volume levels that the in $X.X XXXX, biosimilars a which Global Ibrance increased breast X% grew our global inhibitor of metastatic year grew in million. making totaled to for leader meaningful Ibrance CDKX/X for the biosimilars, our operationally driven a $X.X billion Revenues operationally, oncology generating product growth. XXX% to continues XX% operationally class full $XXX approximately contributor primarily them revenue XXXX. be billion and was mix. from by our This to portfolio in cancer. revenues
XX X out fact, prescribed to a patterns, revenues increased by confident of resulting awareness its Prevnar XXXX, up adult operationally greater uptake billion COVID-XX operationally XX% from metastatic clinical arising physician were everyday continued in pandemic. positive in XXXX. the we in and international driven with in setting. the patients $X.X future U.S. vaccine Revenues markets, experiences, X% certain primarily to and testament performance Ibrance the of outside compelling patients more remain grew Global compelling practice from profile patients the efficacy its metastatic In using received of are on five a than to benefit continued and strong HERX-negative HR-positive, inhibitor who Ibrance safety years in Ibrance. cancer This CDKX/X XX, and with profile. the safety continued U.S. efficacy Based delivers is breast the first-line prescribing
growth. to the that operationally. strong bacteria, indicated XX note of for China also XXXX pneumococcal performance, Inlyta pediatric revenues, prevention resulting contributed is Prevnar this Although from SARS-CoV-X. growing a had uptake in I XX% Strong should not pneumonia
X%. grew in advanced outpacing billion. The with market X% in therapy grew XXXX, underlying prescription XXXX, the the the U.S. year full compared operationally For Global XX% by $X.X demand revenue XXXX Xeljanz to
vital a in not meet this in skin we versus for and did post-marketing invested have which enabling played of non-melanoma TNFi. reported study, top malignancies, the MACE co-primary role U.S., which criteria a data volume cancer in safety line We formulary from Last non-inferiority access week, excluding growth. the the endpoint
to will set priority. discuss impact data assessment and with Xeljanz, to secondary At but to We the patient of the full have endpoints an is as it course, of labeling analyze well this potential the continuing of safety as regulatory through remains point, our may are this study data make implications as agents. the the what premature
grew who U.S. the castration-sensitive combined will starts Xtandi, earlier in our the were For for a of disease, Xtandi is benefit And which year. bolstered their new indication, $X.X the longer royalty billion. duration of with up XX% launch from by successful from sales, totaled alliance for when metastatic helping XX%, income patient revenues ex-U.S. the therapy. patients
days how the collaborate vaccine with to for day and most. submitted us authorization. our to emergency course, for the of Pfizer biggest up develop the Of first COVID-XX FDA authorized be with of work to couldn't to story the plans from in our BioNTech stepped world's get XXX colleagues more to was the announced XXXX day when deliver developed markets. we us took BioNTech just the our It needed I proud the use for we And world use
on capable extraordinary Pfizer was such what of is maintaining Our safety, first ability of. always to display and while the focus move quality speed, powerful new the at our
Pfizer every never past imagined agile scientific of we the we magnitude, capable has manufacturing one the doses doses addressing transform pandemic XXst, that world's to well over only powerhouse, years, government. supplied but vaccine COVID-XX diseases, million XX of were of now. several which a this and commitment taken into devastating action XX as like achieve January XXXX, for happened have an Not been globally, most we the distribution well. While of million as the to of had very we U.S. did our our supplied The gone have
their vaccine first continuing release and receive the time. to Americans the and second U.S. government shipping our doses states We closely with help of to on ensure are schedules work production, on
can obligation. to the specific they U.S. foresee issues so a deliver We have delivering of no government doses million made, the to plan schedule, expect commitments forward-looking by with the end and XXX provided we accordingly. have May, two plants We with vaccinate we produce innovative our earlier more to increase by need explored end Because of of months are people, of to able the the the doses globally than we to number dire have XXXX. contractual
X-dose we as is result, well manufacturers. can a facilities potentially This of our now that on doses at progress as label, at upon end and billion more we contract the X current continuous As believe in adding by contingent improvements XXXX. least and suppliers the total expansion based updated deliver
is pandemic. have seen believe stream so that what the we beginning COVID-XX potential of for far, happening the revenue in it couple vaccine Based on is increasingly We are we now is a reasons. approaching outcome a likely year since durable a flu like of a
vaccine there levels First, will likely a immune maintain to be of elicited to high response. need boost regularly
boost South and neutralized results effectively spikes. variant our SARS-CoV-X who that variant from in The and more need may counter the of during the from spread. engineered to domain people emerging occur maybe of spike recently also with SARS-CoV-X we pseudovirus receptor-binding vaccine threat We and neutralized Second, UK the net and mutations virus we new important, mutations site. sera with studies strains, naturally to mutant in announced variant Africa UK key that the bearing COVID-XX have seen variations spike, have replication received saw vitro
are finding in will our virus by circulation. vaccine’s to encouraged preventing by caused vitro We and variants study COVID-XX in continue the early in monitor this effectiveness
could South variant. are to from We SARS-CoV-X COVID-XX necessary next become an variant. African the with of probable spike neutralization it of boost years set That causing of with awaiting the a is and data increasingly there mutations vaccinated on engineered patients an the a vaccine two when within full spike scenario said,
sequence includes Pfizer to vaccine but an is of the in address mRNA and potentially potential the virus the comparison is to covered utilize to BioNTech -- vaccine to reasons in not it emerge, vaccine. alter one if chose the RNA This ever develop new platform of if the current one were because technologies. flexibility -- if by the strains ability the traditional the of of to the technology for flexibility One
such Of bodies committees as well enable review and to requires make scientific with to updates submissions regulatory Pfizer closely additional and are and working BioNTech regulatory course, possible technical by preparing data approvals. relevant recommendation. to as agencies appropriate a this development vaccine for work and scenario
deploy Regarding infectious diseases viral other plans technology for applications other to vaccines of this flu other outside advancing opportunities and may explore the therapeutic mRNA we platform, applications diseases. on are work and to other
a want the Turning guidance COVID-XX midpoint our few thoughts go guidance. detail. XXXX impact X% now will XXXX to just vaccine. exclude XXXX, our revenue Frank as if into The compared operational growth you our range share of to reflects more completely of to I
out could provide context which recurring signs result, stream, a I remarks. that the revenue revenue may COVID-XX are now. While revenue in we some for both, for there here COVID-XX COVID-XX said, will be Frank time, some carving and anticipated vaccines his margins, our in more as on are
new vaccine dividend, a a growing no While rate. capital and though the has slower COVID-XX initiatives in priorities. We cash on remain flow focused is allocation change stream, created our the there growth at
our continues Now, new be of let's Pfizer great one the strengths. is which the and turn to to engine the for pipeline,
clinical industry improvements start on of average see the to internal assets like As with the and rates is designs. benchmarks. success XXXX tripled I particularly driven successes Between Phase mechanisms scientific with X meetings, pipeline, XXXX XX%. last how we established success these Significantly, built novel benchmark potential compare medicines our and in September's portfolios. discussed an during R&D almost disease, to are from on we appreciated still five-year industry our vaccine most and Investor more rolling our XX%, have either highlighting innovations a of Day first-in-class which in in than they XXXX, incredible of our would XX% double with rates
dosed been We January X call. diseases, X believe since our starts dosed we marstacimab, ambulatory for people at on closed XXXX three-year XX%, the X muscular more B. the benchmark earnings higher accident, patients, flat XX% our points had we We treatment but participant that result announced in the announced to Phase stayed we industry assets clearly achieved points program. of we a through XX to And trial success dystrophy XX in and XX%, the aim November trial the study metrics last that demonstrates first inhibitor research R&D our Our rolling we sustain while end-to-end X countries. is an rate, In are through participant rate Phase than turnaround selecting benchmark. of that a of with average, This than this purposeful of value pipeline. the success rate, XX hemophilia the out anti-tissue of CIFFREO quadrupled X%. factor enroll move would on process, XXrd, in rolling third by not X, demonstrate from point expected X these begun almost the higher the success across to has XXXX. XX%. to our happen our severe triple which X% chance or also study our to did development Duchenne improved sites in was we therapy The Phase benchmark rate XXXX success Phase rare of X, patients. a strategy BASIS than five-year we X being XX%, pathway but average evaluated two we Phase through XX believe XXXX gene from I the benefiting best -- industry On have is ages X of industry had A male clinical this a On science,
here. a address words, has PDUFA XX the other adults the existing investigational many age the October, studies, to later and older, severe priority Our vaccine capture just approved, for profile. abrocitinib DMD expected in patients adults License date oral Application and need with patients. best-in-class to or atopic development. and believe other inflammation, therapy scientific million small not could selective, we potential patients trial demonstrating against for acceptance treatments to pneumococcal in medical PDUFA medicine, to first opportunity in are potential attractive in positive molecule be vitiligo, JAKX-TEC to FDA a the two most of not If cardiovascular ulcerative In from our looking unmet Phase on are date vaccines large will a congresses late-stage Xb comprehensive and applications our In this reported dermatitis for year. one metabolic our current pneumococcal compared strong coverage we these diseases both therapy novel years announced evaluate risk. reduce line pneumococcal moderate cardiovascular of review, and of conjugate underlying to clinical gene XX-valent trial risk results start review We patients with top we in Data Phase X see disease therapies. clinical and the causes of an potentially accepted a care standard of clinical provide rates remission with conjugate vaccine for vaccines, with colitis. XX program for ritlecitinib, other untreated, in progressing X first June. well controlled from is severe with and Phase of is in Many that Last unique priority the and we In the one treat a the There are April. in internal has the initiated vupanorsen for studies Biologics the the EMA filing we simply for In FDA presented hypertriglyceridemia. convert are FDA
trial expect for Our enrolling diabetes shortly. trial we Phase is a to and GLP-X for Phase obesity, oral X initiate our rapidly, X trial
we proof-of-concept ANCHOR first-line robust We step, Braftovi the this pivotal In X the a cancer in study potential the X oncology, a response initiated program. recorded Phase trial. X the and expect for colorectal inform third Phase rates which pivotal readout Phase next will in have quarter year, of
XXXX have for readout We trial, trial, in talazoparib castrate-resistant patients. for readout a X subsequently DDR-plus prostate confidence in outcome of subset expected all-comers the a us cancer Phase positive pivotal TALAPRO-X for the X the of also and increased positive potential which achieved Phase metastatic DDR-plus for gives could TALAPRO-X an in
myeloma myeloma, Phase investigational We multiple or BCMA/CDX for treatment designation trial demonstrated treatment that recently our after bispecific refractory inhibitor, We month. in ongoing are relapsed elranatamab, progressed who initiated anticipate who patients X proteasome or to we X excited of of targeted late response very prior on patients the few potential for least we In presented encouraging in December, multiple with In refractory X and patient January, multiple of a monotherapy elranatamab multiple about from patients one and to with the antibody. this antibody high drug immunomodulatory Fast manageable received myeloma, myeloma. at refractory therapies. Track and data trial the be are rates BCMA-targeted triple-class first X Phase safety relapsed registration-enabling including our elranatamab anti-CDXX dosed
see, As tremendous, you can tremendous activity.
to about I close, Before want words I say a few affordability.
years. working our with transformational from are Biden forward We metrics the year In sustaining And momentum do seen Congress have We a being our we solution, successful over our The of anyone, on this as that goodwill breakthroughs summary, medicines in an in cost or focused it, was past beyond. executive contribution on efforts. and treatment key look breakthrough goodwill great patients. people of deal vaccine aisle and build ensure nimble making can't sides we both on we can to public access COVID-XX to to said, vaccines to we in good remain lower investing forward any working won't and cap As out-of-pocket improvement XXXX to Congress affordably the and build by if we simply can legislation so a with opinion the in we all. through members that help believe the XXXX a them. very action our through look And Company. including status won't a five this and together strong on our R&D and have generated industry has and organization, we accessible on of hope administration, and results for industry
our pipeline. and our At in with risk-adjusted growth our X% on strength development not enhance double-digit on of a to to and XXXX. remain revenue because potential product We a We business of end portfolio opportunities any post growth long-term bottom R&D to our continue time, that growth this CAGR pursue of through the ability the confident achieve XXXX of do at we prospects, our would to will from note rate same these I vaccine. the potential current include least line. the the basis expect projections very COVID-XX impact continue both,
smaller And our value areas. current targets. focus potential on will generation therapeutic are shareholders, as of for We deals Pfizer focused mainly always, those not fit on within acquisition we that
it Now, to and over Frank the turn Frank? to remainder I will the details provide of quarter outlook for XXXX. on our
